These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18175385)

  • 1. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Mehta J
    N Engl J Med; 2008 Jan; 358(1):91; author reply 92-3. PubMed ID: 18175385
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Lokhorst HM; Hazenberg BP; Croockewit A
    N Engl J Med; 2008 Jan; 358(1):92; author reply 92-3. PubMed ID: 18172953
    [No Abstract]   [Full Text] [Related]  

  • 3. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Lachmann HJ; Wechalekar AD; Gillmore JD
    N Engl J Med; 2008 Jan; 358(1):91-2; author reply 92-3. PubMed ID: 18175386
    [No Abstract]   [Full Text] [Related]  

  • 4. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Kumar S; Dispenzieri A; Gertz MA
    N Engl J Med; 2008 Jan; 358(1):91; author reply 92-3. PubMed ID: 18172183
    [No Abstract]   [Full Text] [Related]  

  • 5. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP;
    N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Comenzo RL; Steingart RM; Cohen AD
    N Engl J Med; 2008 Jan; 358(1):92; author reply 92-3. PubMed ID: 18175384
    [No Abstract]   [Full Text] [Related]  

  • 7. Coexistence of primary AL amyloidosis and POEMS syndrome: efficacy of melphalan-dexamethasone and role of biochemical markers in monitoring the diseases course.
    Adami F; Briani C; Binotto G; Altinier S; Tarantini G; Semenzato G
    Am J Hematol; 2010 Feb; 85(2):131-2. PubMed ID: 20029992
    [No Abstract]   [Full Text] [Related]  

  • 8. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
    Sanchorawala V; Seldin DC
    Amyloid; 2007 Dec; 14(4):261-9. PubMed ID: 17968685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of second-line treatment in AL amyloidosis patient's refractory to M-Dex.
    Penot A; Abraham J; Debarri H; Desport E; Aguilar C; Lavergne D; Auroy F; Leleu X; Goldstein A; Kolb B; Bridoux F; Fermand JP; Leblond V; Jaccard A
    Amyloid; 2011 Jun; 18 Suppl 1():145-7. PubMed ID: 21838466
    [No Abstract]   [Full Text] [Related]  

  • 10. Effective and well tolerated treatment with melphalan and dexamethasone for primary systemic AL amyloidosis with cardiac involvement.
    YOSHIZAWA S; AKAHANE D; FUJIMOTO H; GOTOH M; KIGUCHI T; TAUCHI T; OHYASHIKI K
    Rinsho Ketsueki; 2009 Nov; 50(11):1647-51. PubMed ID: 20009442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.
    Palladini G; Milani P; Foli A; Obici L; Lavatelli F; Nuvolone M; Caccialanza R; Perlini S; Merlini G
    Haematologica; 2014 Apr; 99(4):743-50. PubMed ID: 24213149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide.
    Palladini G; Russo P; Lavatelli F; Nuvolone M; Albertini R; Bosoni T; Perfetti V; Obici L; Perlini S; Moratti R; Merlini G
    Ann Hematol; 2009 Apr; 88(4):347-50. PubMed ID: 18779964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis.
    Mignot A; Bridoux F; Thierry A; Varnous S; Pujo M; Delcourt A; Gombert JM; Goujon JM; Favreau F; Touchard G; Herpin D; Jaccard A
    Haematologica; 2008 Mar; 93(3):e32-5. PubMed ID: 18310532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
    Dinner S; Witteles W; Afghahi A; Witteles R; Arai S; Lafayette R; Schrier SL; Liedtke M
    Haematologica; 2013 Oct; 98(10):1593-9. PubMed ID: 23716538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center.
    Tsai SB; Seldin DC; Quillen K; Berk JL; Ruberg FL; Meier-Ewert H; Sloan JM; Doros G; Finn KT; Skinner M; Sanchorawala V
    Blood; 2012 Nov; 120(22):4445-6. PubMed ID: 23175664
    [No Abstract]   [Full Text] [Related]  

  • 16. Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.
    Zhou P; Teruya-Feldstein J; Lu P; Fleisher M; Olshen A; Comenzo RL
    Blood; 2008 Jan; 111(2):549-57. PubMed ID: 17982021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.
    Sanchorawala V; Patel JM; Sloan JM; Shelton AC; Zeldis JB; Seldin DC
    Haematologica; 2013 May; 98(5):789-92. PubMed ID: 23144200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone.
    Bochtler T; Hegenbart U; Kunz C; Benner A; Seckinger A; Dietrich S; Granzow M; Neben K; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
    Amyloid; 2014 Mar; 21(1):9-17. PubMed ID: 24455967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement.
    Dietrich S; Schönland SO; Benner A; Bochtler T; Kristen AV; Beimler J; Hund E; Zorn M; Goldschmidt H; Ho AD; Hegenbart U
    Blood; 2010 Jul; 116(4):522-8. PubMed ID: 20375312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.
    Palladini G; Perfetti V; Obici L; Caccialanza R; Semino A; Adami F; Cavallero G; Rustichelli R; Virga G; Merlini G
    Blood; 2004 Apr; 103(8):2936-8. PubMed ID: 15070667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.